Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist used for chronic weight management, along with a reduced calorie diet and increased physical activity, for people with an initial body mass index (BMI) of: 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, dyslipidemia, obstructive sleep apnea or cardiovascular disease)
Medical supervision ensures proper dosing, lab monitoring, and adjustments based on your bodys unique response
More recently, a long-acting exendin-4-based analog bound to the Fc portion of immunoglobulin G (IgG) known as efpeglenatide is under clinical development, and would also be suitable for a once-weekly injection [8,9]
Resource efficiency
3lp), but rather improves liver and cardiovascular health with slightly greater efficacy than GLP-1RGIPR co-agonism (Fig
Effectiveness and safety of daily oral semaglutide in people with type 2 diabetes mellitus switching from sulfonylureas: A real-world retrospective study
